[go: up one dir, main page]

PE20030066A1 - Composicion de liberacion controlada y metodo para producirla - Google Patents

Composicion de liberacion controlada y metodo para producirla

Info

Publication number
PE20030066A1
PE20030066A1 PE2002000578A PE2002000578A PE20030066A1 PE 20030066 A1 PE20030066 A1 PE 20030066A1 PE 2002000578 A PE2002000578 A PE 2002000578A PE 2002000578 A PE2002000578 A PE 2002000578A PE 20030066 A1 PE20030066 A1 PE 20030066A1
Authority
PE
Peru
Prior art keywords
salt
same
weight
produce
controlled release
Prior art date
Application number
PE2002000578A
Other languages
English (en)
Inventor
Kazumichi Yamamoto
Akiko Yamada
Yoshio Hata
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26617910&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20030066(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of PE20030066A1 publication Critical patent/PE20030066A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • A61K38/09Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/24Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1641Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647Polyesters, e.g. poly(lactide-co-glycolide)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06Antiabortive agents; Labour repressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18Feminine contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/02Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/06Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Molecular Biology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Lubricants (AREA)
  • Moulds For Moulding Plastics Or The Like (AREA)

Abstract

QUE COMPRENDE: 1)DE 14% (p/p) A 24% (p/p), EN BASE AL PESO TOTAL DE LA COMPOSICION, DE UNA SUSTANCIA FISIOLOGICAMENTE ACTIVA O UNA SAL DE LA MISMA; 2)ACIDO HIDROXINAFTOICO SELECCIONADO DE: ACIDO 3-HIDROXI-2-NAFTOICO Y ACIDO 1-HIDROXI-2-NAFTOICO O SAL DEL MISMO; Y, 3)UN POLIMERO DE ACIDO LACTICO O UNA SAL DEL MISMO QUE TIENE UN PESO MOLECULAR MEDIO EN PESO DE 15 000 A 50 000, EN DONDE EL CONTENIDO DE LOS POLIMEROS QUE TIENEN PESOS MOLECULARES DE 5 000 O MENOS ES DE APROXIMADAMENTE EL 5%, EN PESO, O MENOS, SIENDO LA RELACION MOLAR DE (2) O UNA SAL DEL MISMO RESPECTO DE (1) DE 3:4 A 4:3
PE2002000578A 2001-06-29 2002-06-27 Composicion de liberacion controlada y metodo para producirla PE20030066A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001199484 2001-06-29
JP2001340993 2001-11-06

Publications (1)

Publication Number Publication Date
PE20030066A1 true PE20030066A1 (es) 2003-03-20

Family

ID=26617910

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002000578A PE20030066A1 (es) 2001-06-29 2002-06-27 Composicion de liberacion controlada y metodo para producirla

Country Status (33)

Country Link
US (4) US7429559B2 (es)
EP (3) EP1330293B2 (es)
JP (5) JP2003206240A (es)
KR (2) KR100916173B1 (es)
CN (3) CN100577206C (es)
AR (2) AR034641A1 (es)
AT (3) ATE509668T1 (es)
AU (2) AU2002311631B2 (es)
BR (1) BRPI0210561B8 (es)
CA (1) CA2455392C (es)
CO (1) CO5540367A2 (es)
CR (1) CR11283A (es)
CY (2) CY1105071T1 (es)
CZ (1) CZ306327B6 (es)
DE (2) DE60225481T2 (es)
DK (2) DK1330293T4 (es)
ES (2) ES2366677T3 (es)
HU (1) HU230351B1 (es)
IL (3) IL159059A0 (es)
MX (1) MXPA03011456A (es)
MY (1) MY142066A (es)
NO (1) NO331883B1 (es)
NZ (2) NZ541884A (es)
PE (1) PE20030066A1 (es)
PL (1) PL204903B1 (es)
PT (2) PT1330293E (es)
RU (1) RU2301661C2 (es)
SG (1) SG180015A1 (es)
SI (1) SI1949936T1 (es)
SK (1) SK287577B6 (es)
TW (2) TW200526267A (es)
WO (1) WO2003002092A2 (es)
ZA (1) ZA200309152B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1048301A4 (en) 1998-01-16 2005-03-09 Takeda Chemical Industries Ltd COMPOSITIONS WITH DELAYED ACTIVE INGREDIENTS, PROCESS FOR THEIR PREPARATION AND THEIR USE
AR034641A1 (es) * 2001-06-29 2004-03-03 Takeda Pharmaceutical Composicion de liberacion controlada y metodo para producirla
TWI225416B (en) * 2001-06-29 2004-12-21 Takeda Chemical Industries Ltd Sustained-release composition and process for producing the same
CN1662260B (zh) * 2002-06-25 2010-04-28 武田药品工业株式会社 缓释组合物的制备方法
US20070207211A1 (en) * 2003-04-10 2007-09-06 Pr Pharmaceuticals, Inc. Emulsion-based microparticles and methods for the production thereof
CN101410174B (zh) 2003-04-10 2011-04-06 Pr药品有限公司 一种用于生产基于乳化的微观粒子的方法
CA2532302C (en) * 2003-07-15 2016-12-20 Pr Pharmaceuticals, Inc. Method for the preparation of controlled release formulations
AU2004259209A1 (en) 2003-07-23 2005-02-03 Pr Pharmaceuticals, Inc. Controlled release compositions
TW200529890A (en) 2004-02-10 2005-09-16 Takeda Pharmaceutical Sustained-release preparations
TW200613012A (en) * 2004-07-02 2006-05-01 Takeda Pharmaceuticals Co Sustained-release composition, process for producing the same and use of the same
US20060251581A1 (en) * 2005-05-09 2006-11-09 Mcintyre Jon T Method for treatment of uterine fibroid tumors
US20070149457A1 (en) * 2005-12-13 2007-06-28 Byron Rubin Stable solid forms of enterostatin
SI1984009T1 (sl) 2006-01-18 2013-02-28 Qps, Llc Farmacevtski sestavki z izboljĺ ano stabilnostjo
US7858663B1 (en) * 2007-10-31 2010-12-28 Pisgah Laboratories, Inc. Physical and chemical properties of thyroid hormone organic acid addition salts
GEP20125597B (en) 2006-12-18 2012-08-10 Takeda Pharmaceutical Sustained-release composition and production method thereof
US20110319987A1 (en) * 2009-05-20 2011-12-29 Arsenal Medical Medical implant
KR101811797B1 (ko) * 2013-04-03 2017-12-22 동국제약 주식회사 도네페질을 포함하는 비경구투여용 약제학적 조성물
CN105764491A (zh) 2013-12-09 2016-07-13 度瑞公司 药物活性剂复合物、聚合物复合物,以及包括其的组合物和方法
CN103751851A (zh) * 2014-01-17 2014-04-30 东华大学 一种无机/有机多药物控释复合纳米纤维支架的制备方法
KR101558083B1 (ko) * 2014-04-07 2015-10-07 에스케이케미칼주식회사 약물함유 고분자미립구 제조방법
CN106456704A (zh) 2014-04-16 2017-02-22 Veyx-药物有限公司 兽药组合物和其应用
US10787920B2 (en) 2016-10-12 2020-09-29 General Electric Company Turbine engine inducer assembly
KR102089737B1 (ko) 2017-11-01 2020-03-16 한국화학연구원 에씨탈로프람을 함유한 미립구형 서방출 주사제 및 그의 제조방법
TW202432109A (zh) 2022-10-31 2024-08-16 日商武田藥品工業股份有限公司 食慾素2型受體促效劑之給藥
WO2025229492A1 (en) 2024-04-29 2025-11-06 Takeda Pharmaceutical Company Limited Orexin type 2 receptor agonist microcapsules for sustained release dosing
WO2025229493A1 (en) 2024-04-29 2025-11-06 Takeda Pharmaceutical Company Limited Dosing of orexin type 2 receptor agonists

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3297033A (en) * 1963-10-31 1967-01-10 American Cyanamid Co Surgical sutures
US3565869A (en) * 1968-12-23 1971-02-23 American Cyanamid Co Extrudable and stretchable polyglycolic acid and process for preparing same
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3755558A (en) * 1971-02-23 1973-08-28 Du Pont Polylactide drug mixtures for topical application atelet aggregation
US3839297A (en) * 1971-11-22 1974-10-01 Ethicon Inc Use of stannous octoate catalyst in the manufacture of l(-)lactide-glycolide copolymer sutures
US3912692A (en) * 1973-05-03 1975-10-14 American Cyanamid Co Process for polymerizing a substantially pure glycolide composition
US3890283A (en) * 1973-06-04 1975-06-17 American Cyanamid Co Process for post-polymerizing polyglycolic acid
US4258063A (en) 1978-06-23 1981-03-24 Henkel Corporation Self-emulsifying cosmetic base
US4249531A (en) * 1979-07-05 1981-02-10 Alza Corporation Bioerodible system for delivering drug manufactured from poly(carboxylic acid)
US4273920A (en) * 1979-09-12 1981-06-16 Eli Lilly And Company Polymerization process and product
PH19942A (en) 1980-11-18 1986-08-14 Sintex Inc Microencapsulation of water soluble polypeptides
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4479911A (en) * 1982-01-28 1984-10-30 Sandoz, Inc. Process for preparation of microspheres and modification of release rate of core material
US4605730A (en) * 1982-10-01 1986-08-12 Ethicon, Inc. Surgical articles of copolymers of glycolide and ε-caprolactone and methods of producing the same
US4539981A (en) * 1982-11-08 1985-09-10 Johnson & Johnson Products, Inc. Absorbable bone fixation device
FR2537980B1 (fr) * 1982-12-17 1986-12-19 Sandoz Sa Derives d'acides hydroxycarboxyliques oligomeres, leur preparation et leur utilisation
CH656884A5 (de) 1983-08-26 1986-07-31 Sandoz Ag Polyolester, deren herstellung und verwendung.
JPS60100516A (ja) * 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
JPH0678425B2 (ja) 1984-07-06 1994-10-05 和光純薬工業株式会社 重合体の新規製造法
CA1256638A (en) * 1984-07-06 1989-06-27 Motoaki Tanaka Polymer and its production
EP0190833B1 (en) 1985-02-07 1991-03-27 Takeda Chemical Industries, Ltd. Method for producing microcapsule
JP2551756B2 (ja) 1985-05-07 1996-11-06 武田薬品工業株式会社 ポリオキシカルボン酸エステルおよびその製造法
EP0452111B1 (en) * 1990-04-13 1998-07-15 Takeda Chemical Industries, Ltd. Biodegradable high-molecular polymers, production and use thereof
JP3277342B2 (ja) 1992-09-02 2002-04-22 武田薬品工業株式会社 徐放性マイクロカプセルの製造法
US5353086A (en) * 1993-05-03 1994-10-04 Eastman Kodak Company Textured surface with canted channels for an automatic tray processor
DE4342092B4 (de) * 1993-12-09 2007-01-11 Zentaris Gmbh Langwirkende Injektionssuspension und Verfahren zur Herstellung
US5594091A (en) * 1994-02-21 1997-01-14 Takeda Chemical Industries, Ltd. Matrix for sustained-release preparation
JP3490171B2 (ja) 1994-02-21 2004-01-26 武田薬品工業株式会社 生体内分解性ポリマーの末端カルボキシル基におけるエステル
US5763513A (en) * 1994-05-19 1998-06-09 Mitsui Toatsu Chemicals, Inc. L-lactic acid polymer composition, molded product and film
JPH08259460A (ja) * 1995-01-23 1996-10-08 Takeda Chem Ind Ltd 徐放性製剤の製造法
JP3902272B2 (ja) * 1995-09-04 2007-04-04 武田薬品工業株式会社 徐放性製剤の製造法
US5922662A (en) * 1996-08-07 1999-07-13 Colgate Palmolive Company High foaming nonionic surfactant based liquid detergent
ATE272394T1 (de) * 1996-10-31 2004-08-15 Takeda Chemical Industries Ltd Zubereitung mit verzögerter freisetzung
JPH10273447A (ja) * 1997-01-29 1998-10-13 Takeda Chem Ind Ltd 徐放性マイクロスフィア、その製造法および用途
WO1998032423A1 (en) 1997-01-29 1998-07-30 Takeda Chemical Industries, Ltd. Sustained-release microspheres, their production and use
EP1048301A4 (en) * 1998-01-16 2005-03-09 Takeda Chemical Industries Ltd COMPOSITIONS WITH DELAYED ACTIVE INGREDIENTS, PROCESS FOR THEIR PREPARATION AND THEIR USE
JPH11269094A (ja) 1998-01-16 1999-10-05 Takeda Chem Ind Ltd 徐放性組成物、その製造法および用途
US6114495A (en) * 1998-04-01 2000-09-05 Cargill Incorporated Lactic acid residue containing polymer composition and product having improved stability, and method for preparation and use thereof
US6565874B1 (en) * 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
ES2234325T3 (es) * 1998-12-15 2005-06-16 Takeda Pharmaceutical Company Limited Procedimiento para producir poliesteres biodegradables.
JP2000238051A (ja) 1999-02-23 2000-09-05 Kansei Corp 表皮シートの発泡成形型へのセッティング方法
CA2378714A1 (en) * 1999-07-15 2001-01-25 Takeda Chemical Industries, Ltd. Sustained release compositions, methods for producing the same and uses thereof
JP2001081043A (ja) * 1999-07-15 2001-03-27 Takeda Chem Ind Ltd 徐放性組成物、その製造法および用途
JP3837607B2 (ja) 2000-05-29 2006-10-25 Tcm株式会社 マスト用溶接位置決め治具
WO2002012369A1 (en) 2000-08-07 2002-02-14 Wako Pure Chemical Industries, Ltd. Lactic acid polymer and process for producing the same
WO2002043766A1 (en) * 2000-11-29 2002-06-06 Takeda Chemical Industries, Ltd. Medicinal compositions and process for producing the same
WO2002047722A1 (en) 2000-12-15 2002-06-20 Takeda Chemical Industries, Ltd. Medicinal compositions of nonpeptidyl gonadotropin-releasing hormone agonist or antagonist, process for producing the same and use thereof
AR034641A1 (es) * 2001-06-29 2004-03-03 Takeda Pharmaceutical Composicion de liberacion controlada y metodo para producirla

Also Published As

Publication number Publication date
DK1949936T3 (da) 2011-08-15
BRPI0210561B8 (pt) 2021-05-25
EP1330293A2 (en) 2003-07-30
JP2004238400A (ja) 2004-08-26
US8815801B2 (en) 2014-08-26
CN1535168A (zh) 2004-10-06
CA2455392C (en) 2011-11-22
HK1056332A1 (en) 2004-02-13
WO2003002092A3 (en) 2003-04-10
EP1949936A2 (en) 2008-07-30
MXPA03011456A (es) 2004-07-01
HUP0400378A2 (hu) 2004-12-28
NZ529969A (en) 2005-10-28
AU2002311631B2 (en) 2007-02-08
EP1330293B1 (en) 2006-05-17
DE60225481T2 (de) 2009-02-26
US8067030B2 (en) 2011-11-29
SK15602003A3 (sk) 2004-06-08
WO2003002092A2 (en) 2003-01-09
CR11283A (es) 2010-05-31
BR0210561A (pt) 2004-06-22
DK1330293T4 (da) 2011-01-10
PT1949936E (pt) 2011-07-12
US8246987B2 (en) 2012-08-21
ES2263788T5 (es) 2011-02-22
ATE509668T1 (de) 2011-06-15
NO20035738D0 (no) 2003-12-19
CN100577206C (zh) 2010-01-06
KR100916173B1 (ko) 2009-09-08
NO20035738L (no) 2004-02-27
DE60211464T2 (de) 2006-09-07
EP1491236A1 (en) 2004-12-29
US20090005318A1 (en) 2009-01-01
CN100348265C (zh) 2007-11-14
MY142066A (en) 2010-08-30
AU2006246508B2 (en) 2008-09-04
KR100961413B1 (ko) 2010-06-09
DE60211464T3 (de) 2011-03-17
CY1111708T1 (el) 2015-10-07
CO5540367A2 (es) 2005-07-29
ES2263788T3 (es) 2006-12-16
IL186782A0 (en) 2008-02-09
EP1491236B1 (en) 2008-03-05
CY1105071T1 (el) 2010-03-03
JP2010189427A (ja) 2010-09-02
CN1724066A (zh) 2006-01-25
ZA200309152B (en) 2005-01-26
EP1949936B1 (en) 2011-05-18
PT1330293E (pt) 2006-08-31
US7429559B2 (en) 2008-09-30
ES2366677T3 (es) 2011-10-24
AR098261A2 (es) 2016-05-18
PL204903B1 (pl) 2010-02-26
US20030134800A1 (en) 2003-07-17
AR034641A1 (es) 2004-03-03
ATE387937T1 (de) 2008-03-15
CZ20033493A3 (cs) 2004-08-18
JP4819173B2 (ja) 2011-11-24
JP2009167203A (ja) 2009-07-30
EP1330293B2 (en) 2010-10-27
CA2455392A1 (en) 2003-01-09
US20120283187A1 (en) 2012-11-08
RU2004102507A (ru) 2005-03-10
HU230351B1 (hu) 2016-02-29
TW200526267A (en) 2005-08-16
CZ306327B6 (cs) 2016-12-07
IL159059A0 (en) 2004-05-12
DE60225481D1 (de) 2008-04-17
KR20040018402A (ko) 2004-03-03
TWI332407B (en) 2010-11-01
US20110166084A1 (en) 2011-07-07
DK1330293T3 (da) 2006-09-11
JP4819172B2 (ja) 2011-11-24
JP2010189428A (ja) 2010-09-02
IL159059A (en) 2011-06-30
JP2003206240A (ja) 2003-07-22
SK287577B6 (sk) 2011-03-04
CN1868458A (zh) 2006-11-29
EP1949936A3 (en) 2008-10-08
KR20090020708A (ko) 2009-02-26
BRPI0210561B1 (pt) 2018-08-14
SG180015A1 (en) 2012-05-30
HUP0400378A3 (en) 2010-01-28
AU2006246508A1 (en) 2006-12-21
SI1949936T1 (sl) 2011-08-31
CN1292796C (zh) 2007-01-03
ATE326264T1 (de) 2006-06-15
DE60211464D1 (de) 2006-06-22
RU2301661C2 (ru) 2007-06-27
PL367518A1 (pl) 2005-02-21
NO331883B1 (no) 2012-04-23
NZ541884A (en) 2007-01-26

Similar Documents

Publication Publication Date Title
PE20030066A1 (es) Composicion de liberacion controlada y metodo para producirla
CY1109272T1 (el) Συνθεση παρατεταμενης απελευθερωσεως περιλαμβανουσα συμπολυμερες γαλακτικου οξεος-γλυκολικου οξεος και μεθοδος παρασκευης της
ES2422681T3 (es) Formulación de fármaco de moléculas pequeñas de liberación prolongada
AR041114A1 (es) Particulas polimericas que tienen grupos pendientes seleccionados y composicion preparada a partir de las mismas
CY1118798T1 (el) Συνθεση της διαδερμικης παροχης φαιντανυλης
BRPI0509842A (pt) composição amaciante para tecidos, e, método para conferir maciez a tecidos
ATE521373T1 (de) Knochenzementzusammensetzung
NZ610346A (en) Hyaluronic acid based formulations
BR0313424A (pt) Forma de dosagem e processo para a preparação de uma forma de dosagem
BR0113608A (pt) Composição cosmética clara em emulsão antiperspirante e/ou desodorante
AR082862A1 (es) Forma de dosificacion resistente a alteracion que comprende un polimero anionico
BRPI0210722B8 (pt) implantes injetáveis biodegradáveis e métodos relacionados de produção e uso
ES2173999T3 (es) Dispersante de cemento, metodo para la produccion del mismo y composicion de cemento que utiliza el dispersante.
BR0212169A (pt) Composição polimérica, processos para a preparação da mesma e de um derivado de poliisobuteno, e, derivado de poliisobuteno
CO5570652A2 (es) Productos en gel para la axila, con componente de bloqueo de agua
BR0008091A (pt) Material de sutura de feridas, e, material
EP2123257A3 (en) Stable high Vitamin C content polyol-in-oil emulsified system and its preparation
BR0316437A (pt) Composição cosmeticamente aceitável para tratamento da pele, e, método para tratar a pele
ATE432962T1 (de) Bioabsorbierbare polymerzusammensetzungen mit erhöhten kristallisations- und hydrolyseraten
TR201909466T4 (tr) Düşük serbest stearik asit içeren veya tespit edilebilen hiç serbest stearik asit içermeyen, stearik asitle işlenmiş kalsiyum karbonat bileşimleri ve ilgili yöntemler.
ATE360413T1 (de) Zusammensetzungen mit verzögerter freigabe, verfahren zu deren herstellung und verwendung
BR0315563A (pt) Dispersões poliméricas estáveis e processos para sua preparação
BR9710315A (pt) Inibidores de polimerização.
BR0207919A (pt) Método para a preparação de uma micropartìcula homogênea de metoprolol, micropartìcula, composição farmacêutica, método para prevenir ou tratar um distúrbio cardiovascular em um mamìfero, e, uso de uma micropartìcula
DE502005002688D1 (de) Verfahren zur herstellung von hochverzweigten polyamiden

Legal Events

Date Code Title Description
FG Grant, registration